An experimental, mRNA-based cancer vaccine significantly reduced the risk that melanoma patients’ cancers would return and be fatal, Moderna and Merck said, in what the companies are calling the first-ever results from an mRNA therapy in a randomized trial of cancer patients.
In the Phase II trial, patients with Stage 3 or Stage 4 melanoma got Merck’s drug Keytruda, plus doses of a personalized cancer vaccine called mRNA-4157/V940 that the two developed jointly. Nine months later, the treatment had reduced the risk of recurrence or death by 44%, compared with Keytruda alone, the companies said Tuesday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,400+ biopharma pros reading Endpoints daily — and it’s free.
Read More: Sanofi teams up science and sports for Paris 2024 Olympics sponsorship, extending its
